イヴァルメクチンと婦人科がん データは?
Vaidehi Mujumdar1, Marilyn Huang2, Lindsey Chippendale Smith3
1Atrium Health Levine Cancer Institute, 1021 Morehead Drive, Suite 2100, Charlotte, NC 28202, USA.
Gynecologic oncology reports
|August 25, 2025
まとめ
寄生虫感染症に承認されたイヴァルメクチンは,婦人科がん治療に関するデータがない. 研究者は,安全性と有効性の証拠が不十分であるため,婦人科がんでの使用に対して注意を払う.
科学分野:
- 婦人科腫瘍学
- 薬理学について
- 薬物の再利用
背景:
- イヴァルメクチンは ストロングロイド病やオンコサーキアスのような 寄生虫感染症の治療にFDAの認可を受けています
- イバメクチンの抗がん性に関する現存の研究は,主にインビトロ細胞系研究に限られている.
- 婦人科がんの治療薬としてのイヴァルメクチンの可能性に関する包括的なデータは不足しています.
研究 の 目的:
- 婦人科がんにおけるイヴァルメクチンの使用に関する現在の根拠を評価する.
- この患者集団におけるイヴァルメクチンの安全性と有効性に関する知識のギャップを特定する.
- 婦人腫瘍学におけるイヴァルメクチンの有用性に関する臨床的勧告を提供すること.
主な方法:
- 癌におけるイヴァルメクチンに関する既存の臨床試験と臨床前データの文献レビュー
- FDAが承認したイヴァルメクチン用薬の分析
- 具体的には婦人科がんの適用のための利用可能な証拠の評価.
主要な成果:
- 婦人科がんに対するivermectinの有効性に関する現在のデータは存在しない.
- 癌治療のためのイヴァルメクチンの臨床試験は,細胞線観察に限定されています.
- 婦人科がんの治療におけるイヴァルメクチンの安全性と有効性は臨床的に評価されていません.
結論:
- 婦人科がんの治療にイヴァルメクチンの使用は,現在の臨床証拠によって支持されていません.
- 婦人科がんの治療では,イヴァルメクチンの使用は厳格に注意すべきです.
- 婦人腫瘍学におけるイヴァルメクチンの潜在的な作用を決定するには,さらなる厳密な臨床試験が必要である.
関連する概念動画
01:21Cancer Survival Analysis
453
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
453
01:07Teratogenicity
2.7K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.7K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
01:28Infertility in Females
401
Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of...
Endometriosis, a condition characterized by abnormal growth of...
401
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K